A phase IIb trial to investigate the efficacy of GALE-301/GALE-302 in ovarian cancer

Trial Profile

A phase IIb trial to investigate the efficacy of GALE-301/GALE-302 in ovarian cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2016

At a glance

  • Drugs GALE 301 (Primary) ; GALE 302 (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jan 2016 New trial record
    • 13 Jan 2016 The company plans to initiate this trial in the second half of 2016, according to a Galena Biopharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top